11 completed, 6 terminated, 3 active not recruiting, 3 withdrawn. 17 Phase 2, 14 Phase 1.
Follow AZD2014: new trials by email Literature Review of AZD2014 trials Research Report on AZD2014
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors Navitoclax, Vistusertib - Metastatic Malignant Solid Neoplasm, Recurrent Lung Small Cell Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 15 | 2018-03-20 | 2023-10-17 |
| Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy Vistusertib(AZD2014) - Solid Tumor | Phase 2 | Withdrawn | Samsung Medical Center | 2018-03-01 | 2019-05-20 | |
| Phase II Trial of Vistusertib（AZD2014） Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard Chemotherapy Vistusertib(AZD2014) - Solid Tumor | Phase 2 | Withdrawn | Samsung Medical Center | 2018-03-01 | 2019-05-20 | |
| Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas AZD2014 - Meningioma | Phase 2 | Active not recruiting | Massachusetts General Hospital | 28 | 2017-10-17 | 2022-10-18 |
| A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies acalabrutinib, vistusertib - DLBCL, Richter Syndrome | Phase 1 / Phase 2 | Terminated | Acerta Pharma BV | 25 | 2017-06-29 | 2021-01-06 |
| Trial of Single Agent AZD2014 in RICTOR Amplified GC Patients as Second-line Therapy AZD2014 - Stomach Neoplasms | Phase 2 | Terminated | Samsung Medical Center | 1 | 2017-02-01 | 2019-05-20 |
| Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy AZD2014 - Cancer of Stomach | Phase 2 | Terminated | Samsung Medical Center | 1 | 2017-02-01 | 2019-05-20 |
| mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme AZD2014 - Glioblastoma Multiforme | Phase 1 | Completed | Canadian Cancer Trials Group | 15 | 2016-12-22 | 2023-08-04 |
| AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas AZD2014 - Neurofibromatosis 2, Meningioma | Phase 2 | Completed | Massachusetts General Hospital | 18 | 2016-08-31 | 2022-06-13 |
| European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors Ribociclib, Topotecan, Temozolomide - Pediatric Cancer | Phase 1 / Phase 2 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 472 | 2016-08-03 | 2026-07-10 |
| AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma AZD2014, Ibrutinib - Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Module 1: Non-GCB Diffuse Large B-Cell Lymphoma | Phase 1 | Withdrawn | AstraZeneca | 2016-06-01 | 2016-09-15 | |
| Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA) AZD2014, Anastrozole - Endometrial Carcinoma, Metastatic Carcinoma | Phase 1 / Phase 2 | Unknown | Centre Leon Berard | 72 | 2016-04-01 | 2024-02-13 |
| Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer AZD2014, Palbociclib, Fulvestrant - Advanced and Metastatic Breast Cancer | Phase 1 | Completed | AstraZeneca | 54 | 2015-12-07 | 2024-06-06 |
| A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers AZD2014, AZD6244 - Triple-Negative Breast Cancer, Squamous Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | Queen Mary University of London | 118 | 2015-06-01 | 2020-02-25 |
| National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer AZD4547, Vistusertib, Palbociclib - Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell | Phase 2 | Completed | University of Birmingham | 423 | 2015-05-13 | 2026-04-28 |
| Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies AZD2014 - Advanced Solid Malignancies | Phase 1 | Completed | AstraZeneca | 28 | 2015-03-17 | 2024-12-17 |
| Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy AZD5363, paclitaxel, AZD2014 - Advanced Gastric Adenocarcinoma | Phase 2 | Terminated | Samsung Medical Center | 27 | 2015-02-12 | 2019-05-20 |
| mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Capivasertib, Laboratory Biomarker Analysis, Olaparib - BRCA1 Mutation Carrier, BRCA2 Mutation Carrier | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 159 | 2014-11-11 | 2026-09-04 |
| Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer AZD2014 - Prostate Cancer | Phase 1 | Completed | Cambridge University Hospitals NHS Foundation Trust | 23 | 2014-10-01 | 2019-07-17 |
| SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients AZD2014, AZD4547, AZD5363 - Non-small Cell Lung Cancer Metastatic | Phase 2 | Completed | UNICANCER | 999 | 2014-04-23 | 2024-01-10 |
Showing 20 of 26. Sign in to see all of them.
Breast Neoplasms (3) · Neoplasms (3) · Meningioma (2) · Stomach Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Adenocarcinoma (1) · Carcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Disease (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Glioblastoma (1) · Lung Neoplasms (1)
AstraZeneca (5) · Samsung Medical Center (5) · Queen Mary University of London (3) · Massachusetts General Hospital (2) · UNICANCER (2) · Acerta Pharma BV (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Canadian Cancer Trials Group (1) · Centre Leon Berard (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Royal Marsden NHS Foundation Trust (1) · University of Birmingham (1)
United Kingdom (10) · United States (7) · South Korea (6) · France (5) · Spain (2) · Canada (1) · Denmark (1) · Georgia (1) · Germany (1) · Hungary (1) · Italy (1) · Japan (1) · Netherlands (1) · Portugal (1) · Romania (1)
Anja Wiliams (1) · Birgit Geoerger, MD (1) · Christine L Hann (1) · Dr. Udai Banerji (1) · Elisabeth Oelmann (1) · Gary W Middleton (1) · Ian W Flinn, MD, PhD (1) · Jeeyun Lee, Md,PhD (1) · Peter Schmid, Prof (1) · Peter Schmid, Professor (1)
PMID 26410619, PMID 30016392, PMID 31465093, PMID 31538815, PMID 31707687, PMID 32067679, PMID 32379297, PMID 32669708, PMID 33892407, PMID 34269152, PMID 34347542, PMID 34543871, PMID 35292802, PMID 35551299, PMID 39998620, PMID 40069402, PMID 41838385, PMID 42686334
2014 (3), 2009 (1), 2015 (1), 2016 (1), P50CA083639 (1), R01CA201130 (1), UM1CA186691 (1)